Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma

Carla Casulo, Maria Arcila, Olga L. Bohn, Julie Teruya-Feldstein, Jocelyn Maragulia, Craig Moskowitz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Growing evidence demonstrates that an increased number of CD68 positive tumor-associated macrophages (TAM) is associated with decreased survival in patients with newly diagnosed classic Hodgkin lymphoma (HL). However, the impact of TAM in relapsed and refractory disease is unknown. Design and methods: To investigate whether the presence of elevated CD68 retains its prognostic significance in the relapsed and refractory setting, we analyzed pre-salvage biopsy specimens of 81 patients with relapsed and refractory HL using a tissue microarray. Scoring of CD68 was based on the percentage of CD68 positive TAM compared to the total number of cells in representative areas. The final percent of CD68 positivity for each case was based on the average of cores available for examination. Results: In a univariate analysis, we found that patients with elevated levels of CD68 positive TAM had inferior overall survival (OS) compared with patients who had lower CD68 levels. For patients undergoing autologous stem cell transplant after salvage treatment, elevated CD68 levels were predictive of both adverse OS and event free survival. However, after adjusting for other variables, increased CD68 positive TAM did not retain prognostic significance in a multivariate model. Conclusions: In our dataset of primary refractory and relapsed Hodgkin lymphoma biopsy specimens, TAM infiltration is unable to definitively predict outcome. In order to validate these findings, TAM infiltration of relapsed and refractory specimens should be assessed prospectively and paired to initial Hodgkin lymphoma biopsies at diagnosis.

Original languageEnglish (US)
Pages (from-to)1178-1183
Number of pages6
JournalLeukemia Research
Volume37
Issue number9
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Hodgkin Disease
Macrophages
Neoplasms
Biopsy
Survival
Salvage Therapy
Disease-Free Survival
Stem Cells
Cell Count
Transplants

Keywords

  • CD68
  • Hodgkin lymphoma
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Casulo, C., Arcila, M., Bohn, O. L., Teruya-Feldstein, J., Maragulia, J., & Moskowitz, C. (2013). Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma. Leukemia Research, 37(9), 1178-1183. https://doi.org/10.1016/j.leukres.2013.03.021

Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma. / Casulo, Carla; Arcila, Maria; Bohn, Olga L.; Teruya-Feldstein, Julie; Maragulia, Jocelyn; Moskowitz, Craig.

In: Leukemia Research, Vol. 37, No. 9, 01.09.2013, p. 1178-1183.

Research output: Contribution to journalArticle

Casulo, C, Arcila, M, Bohn, OL, Teruya-Feldstein, J, Maragulia, J & Moskowitz, C 2013, 'Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma', Leukemia Research, vol. 37, no. 9, pp. 1178-1183. https://doi.org/10.1016/j.leukres.2013.03.021
Casulo, Carla ; Arcila, Maria ; Bohn, Olga L. ; Teruya-Feldstein, Julie ; Maragulia, Jocelyn ; Moskowitz, Craig. / Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma. In: Leukemia Research. 2013 ; Vol. 37, No. 9. pp. 1178-1183.
@article{317fecd2d1a740e49965a848527f8013,
title = "Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma",
abstract = "Background: Growing evidence demonstrates that an increased number of CD68 positive tumor-associated macrophages (TAM) is associated with decreased survival in patients with newly diagnosed classic Hodgkin lymphoma (HL). However, the impact of TAM in relapsed and refractory disease is unknown. Design and methods: To investigate whether the presence of elevated CD68 retains its prognostic significance in the relapsed and refractory setting, we analyzed pre-salvage biopsy specimens of 81 patients with relapsed and refractory HL using a tissue microarray. Scoring of CD68 was based on the percentage of CD68 positive TAM compared to the total number of cells in representative areas. The final percent of CD68 positivity for each case was based on the average of cores available for examination. Results: In a univariate analysis, we found that patients with elevated levels of CD68 positive TAM had inferior overall survival (OS) compared with patients who had lower CD68 levels. For patients undergoing autologous stem cell transplant after salvage treatment, elevated CD68 levels were predictive of both adverse OS and event free survival. However, after adjusting for other variables, increased CD68 positive TAM did not retain prognostic significance in a multivariate model. Conclusions: In our dataset of primary refractory and relapsed Hodgkin lymphoma biopsy specimens, TAM infiltration is unable to definitively predict outcome. In order to validate these findings, TAM infiltration of relapsed and refractory specimens should be assessed prospectively and paired to initial Hodgkin lymphoma biopsies at diagnosis.",
keywords = "CD68, Hodgkin lymphoma, Refractory, Relapsed",
author = "Carla Casulo and Maria Arcila and Bohn, {Olga L.} and Julie Teruya-Feldstein and Jocelyn Maragulia and Craig Moskowitz",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2013.03.021",
language = "English (US)",
volume = "37",
pages = "1178--1183",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma

AU - Casulo, Carla

AU - Arcila, Maria

AU - Bohn, Olga L.

AU - Teruya-Feldstein, Julie

AU - Maragulia, Jocelyn

AU - Moskowitz, Craig

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Growing evidence demonstrates that an increased number of CD68 positive tumor-associated macrophages (TAM) is associated with decreased survival in patients with newly diagnosed classic Hodgkin lymphoma (HL). However, the impact of TAM in relapsed and refractory disease is unknown. Design and methods: To investigate whether the presence of elevated CD68 retains its prognostic significance in the relapsed and refractory setting, we analyzed pre-salvage biopsy specimens of 81 patients with relapsed and refractory HL using a tissue microarray. Scoring of CD68 was based on the percentage of CD68 positive TAM compared to the total number of cells in representative areas. The final percent of CD68 positivity for each case was based on the average of cores available for examination. Results: In a univariate analysis, we found that patients with elevated levels of CD68 positive TAM had inferior overall survival (OS) compared with patients who had lower CD68 levels. For patients undergoing autologous stem cell transplant after salvage treatment, elevated CD68 levels were predictive of both adverse OS and event free survival. However, after adjusting for other variables, increased CD68 positive TAM did not retain prognostic significance in a multivariate model. Conclusions: In our dataset of primary refractory and relapsed Hodgkin lymphoma biopsy specimens, TAM infiltration is unable to definitively predict outcome. In order to validate these findings, TAM infiltration of relapsed and refractory specimens should be assessed prospectively and paired to initial Hodgkin lymphoma biopsies at diagnosis.

AB - Background: Growing evidence demonstrates that an increased number of CD68 positive tumor-associated macrophages (TAM) is associated with decreased survival in patients with newly diagnosed classic Hodgkin lymphoma (HL). However, the impact of TAM in relapsed and refractory disease is unknown. Design and methods: To investigate whether the presence of elevated CD68 retains its prognostic significance in the relapsed and refractory setting, we analyzed pre-salvage biopsy specimens of 81 patients with relapsed and refractory HL using a tissue microarray. Scoring of CD68 was based on the percentage of CD68 positive TAM compared to the total number of cells in representative areas. The final percent of CD68 positivity for each case was based on the average of cores available for examination. Results: In a univariate analysis, we found that patients with elevated levels of CD68 positive TAM had inferior overall survival (OS) compared with patients who had lower CD68 levels. For patients undergoing autologous stem cell transplant after salvage treatment, elevated CD68 levels were predictive of both adverse OS and event free survival. However, after adjusting for other variables, increased CD68 positive TAM did not retain prognostic significance in a multivariate model. Conclusions: In our dataset of primary refractory and relapsed Hodgkin lymphoma biopsy specimens, TAM infiltration is unable to definitively predict outcome. In order to validate these findings, TAM infiltration of relapsed and refractory specimens should be assessed prospectively and paired to initial Hodgkin lymphoma biopsies at diagnosis.

KW - CD68

KW - Hodgkin lymphoma

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=84880961819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880961819&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.03.021

DO - 10.1016/j.leukres.2013.03.021

M3 - Article

VL - 37

SP - 1178

EP - 1183

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -